MedTrace Logo

Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan

NCT03136328 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2023-05-09

Study results available
· View outcomes & findings →

Summary

The primary goal of the analysis is to estimate the diagnostic accuracy of Gallium 68 (68Ga) -DOTATOC PET/CT for detecting neuroendocrine tumors (NETs) compared to conventional imaging techniques such as Magnetic Resonance Imaging (MRI) and Computerized Tomography (CT). Participants with histologically and/or clinically confirmed and/or suspected NET will be enrolled.

Conditions

Interventions

DRUG

68Ga-DOTATOC

The intervention is to administer 68Ga-DOTATOC PET/CT for detecting NET.

Sponsors & Collaborators

  • NCM USA

    collaborator UNKNOWN

  • Montefiore Medical Center

    lead OTHER

Principal Investigators

  • Charito Love, MD · Montefiore Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-05-16
Primary Completion
2017-03-31
Completion
2017-03-31
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03136328 on ClinicalTrials.gov